This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (6)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Therapy With Ingested Immunomodulatory Proteins

Staley A. Brod, MD

Arch Neurol. 1997;54(10):1300-1302.

Abstract
The recent negative results of the 2-year phase III trial of enteral myelin (Myloral), a preparation of bovine myelin given orally in multiple sclerosis (MS), warn that the efficacy of oral tolerization (ie, inducing hyporesponsiveness to a specific autoantigen) and the attractiveness of oral desensitization in animal models of MS may not translate into clinical practice. However, such failure should not deter further examination of the mouth, an immunologically interesting and patient-friendly route for immunomodulatory proteins.

Author Affiliations
From the Department of Neurology, Multiple Sclerosis Research Group, University of Texas Health Science Center at Houston.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Ingested Type I Interferon: State of the Art as Treatment for Autoimmunity
Brod
Exp. Biol. Med. 2002;227:981-988.
ABSTRACT | FULL TEXT